Evidence map›Paper›PMID 35347542›Full record

ArticleMolecular biology reports2022

Farnesoid X receptor functions in cervical cancer via the p14

Xiaohua Huang, Bin Wang, Huimin Shen, Danmei Huang, Ganggang Shi

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecular biology reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.9field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Xiaohua HuangDepartment of Pediatrics, Second Affiliated Hospital of Shantou University Medical College, Shantou, China. xhhuang2@foxmail.com.ORCID http://orcid.org/0000-0002-6411-3966
Bin WangDepartment of Pharmacology, Shantou University Medical College, Shantou, China.
Huimin ShenDepartment of Neurology, Second Affiliated Hospital of Shantou University Medical College, Shantou, China.
Danmei HuangDepartment of Pharmacology, Shantou University Medical College, Shantou, China.
Ganggang ShiDepartment of Pharmacology, Shantou University Medical College, Shantou, China.
Shantou University · CN

Funding

Medical Science and Technology Foundation of Guangdong Province 20181031201648512
6 · The paper itself

Abstract

backgroundCervical cancer is the second most common cancer among women living in developing countries. Farnesoid X receptor (FXR) is a member of the nuclear receptor family, which regulates the development and proliferation of cancer. However, the role of and molecular mechanism by which FXR acts in cervical cancer are still unknown. METHODS AND

resultsThe relationship between FXR and the proliferation of cervical cancer cell lines was detected by MTT and colony formation assays. Immunohistochemistry was used to detect the expression of FXR in cervical cancer tissue slides. Western blotting was used to detect the expression of p14

conclusionsFXR inhibits cervical cancer by upregulating the p14

Indexed as

Proto-Oncogene Proteins c-mdm2Receptors, Cytoplasmic and NuclearTumor Suppressor Protein p14ARFTumor Suppressor Protein p53Uterine Cervical NeoplasmsFemaleHumansReceptor, Farnesoid X-ActivatedMDM2 protein, humanProto-Oncogene Proteins c-mdm2Receptor, Farnesoid X-ActivatedReceptors, Cytoplasmic and NuclearTP53 protein, humanTumor Suppressor Protein p14ARFTumor Suppressor Protein p53Cervical cancerFXRMDM2p14ARFp53

Identifiers

PMID35347542
PMCPMC9174312
OpenAlexW4220740245

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.